Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial

Eli Lilly’s triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today.  Retatrutide is an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist. The drug met the primary and key secondary endpoints, delivering superior A1C reduction and… The post Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial appeared first on Drug Discovery and Development.

Continue reading →